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Behavioral, neurochemical and morphological
changes induced by the overexpression of munc18-1a
in brain of mice: relevance to schizophrenia
L Urigu¨en1,2,3, I Gil-Pisa1,2, E Munarriz-Cuezva1,2, E Berrocoso1,4, J Pascau1,5, ML Soto-Montenegro1,5, A Gutie´rrez-Ada´n6, B Pintado6,
JLM Madrigal1,7, E Castro1,8, P Sa´nchez-Bla´zquez1,9, JE Ortega1,2,3, MJ Guerrero10, M Ferrer-Alcon10, JA Garcı´a-Sevilla11, JA Mico´1,4,
M Desco1,5,12, JC Leza1,7, A´ Pazos1,8, J Garzo´n1,9 and JJ Meana1,2,3
Overexpression of the mammalian homolog of the unc-18 gene (munc18-1) has been described in the brain of subjects with
schizophrenia. Munc18-1 protein is involved in membrane fusion processes, exocytosis and neurotransmitter release.
A transgenic mouse strain that overexpresses the protein isoform munc18-1a in the brain was characterized. This animal
displays several schizophrenia-related behaviors, supersensitivity to hallucinogenic drugs and deficits in prepulse inhibition
that reverse after antipsychotic treatment. Relevant brain areas (that is, cortex and striatum) exhibit reduced expression
of dopamine D1 receptors and dopamine transporters together with enhanced amphetamine-induced in vivo dopamine release.
Magnetic resonance imaging demonstrates decreased gray matter volume in the transgenic animal. In conclusion, the mouse
overexpressing brain munc18-1a represents a new valid animal model that resembles functional and structural abnormalities in
patients with schizophrenia. The animal could provide valuable insights into phenotypic aspects of this psychiatric disorder.
Translational Psychiatry (2013) 3, e221; doi:10.1038/tp.2012.149; published online 22 January 2013
Introduction
Schizophrenia is a chronic and disabling psychiatric disorder
that affects about 1% of the population worldwide. Symptoms
of schizophrenia include positive, negative and cognitive
deficits.1 The hypothesis that dopaminergic mechanisms play
an important role in the pathophysiology of schizophrenia has
been one of the most accepted ideas about the disease.2
In addition, in vivo neuroimaging studies have demonstrated
reduced gray matter volume in patients with schizophrenia.3,4
Although the processes involved in the development
of schizophrenia remain unclear, it has been suggested that
dysfunctions in neuroexocytosis could be a key point in the
pathophysiology of the disorder.5
The proteins responsible for the mechanism of
membrane fusion and neurotransmitter release (SNAP-25,
syntaxin-1A and synaptobrevin) form the SNARE (soluble
N-ethylmaleimide-sensitive factor attachment protein recep-
tors).6 Munc18-1 interacts with syntaxin-1A and other SNARE
proteins, and influences all of the steps leading to exocytosis,
including vesicle recruitment, docking and membrane
fusion.7,8 It has been proposed that abnormalities of
munc18-1 and/or SNARE proteins might participate in the
pathogenesis of schizophrenia underlying dysfunctional
neuroexocytosis.5,9 Thus, proteomic studies in postmortem
prefrontal cortex of subjects with schizophrenia have shown
increases of munc18-1 in membrane microdomains of
the gray matter.10 Moreover, antipsychotic treatment seems
to be associated with a lower content of key proteins of the
exocytotic machinery, which could results in a destabilization/
impairment of neuroexocytosis.11
Alternative splicing of the gene coding for munc18-1 results
in two variants, the long isoform (munc18-1a, brain and retina)
and the ubiquitous short isoform (munc18-1b).12,13
A wide number of animal models of schizophrenia have
been developed14 in an effort to reproduce one or more of the
symptoms observed in humans. Animal models represent a
very useful tool for the study of the mechanisms underlying
schizophrenia-like behaviors and for the evaluation of the
therapeutic efficacy of antipsychotics.14,15 In this context, a
transgenic mouse overexpressing the isoform munc18-1a
protein was developed to assess whether abnormalities
of exocytosis machinery could lead to emergence of
schizophrenic phenotypes.
Materials and methods
All animal studies were performed in accordance with the
European Directive for the Protection of Vertebrate Animals
1Centro de Investigacio´n Biome´dica en Red de Salud Mental CIBERSAM, Spain; 2Department of Pharmacology, University of the Basque Country UPV/EHU Leioa,
Bizkaia, Spain; 3BioCruces Health Research Institute, Bizkaia, Spain; 4Department of Neuroscience, University of Ca´diz, Ca´diz, Spain; 5Department of Experimental
Medicine and Surgery, General Hospital Gregorio Maran˜o´n, Madrid, Spain; 6Department of Animal Reproduction, INIA, Madrid, Spain; 7Department of Pharmacology,
Faculty of Medicine, Complutense University, Madrid, Spain; 8Department of Physiology and Pharmacology, University of Cantabria, Institute of Biomedicine and
Biotechnology of Cantabria IBBTEC), Santander, Spain; 9Cajal Institute, CSIC, Madrid, Spain; 10Brainco Biopharma, SL, Derio, Bizkaia, Spain; 11Neuropharmacology
Laboratory, IUNICS, University of Balearic Islands, Palma de Mallorca and Redes Tema´ticas de Investigacio´n Cooperativa en Salud, Red de Trastornos Adictivos
(RETICS-RTA), Spain and 12Department of Bioengineering and Aerospace Engineering, Carlos III University, Madrid, Spain
Correspondence: Dr JJ Meana, Department of Pharmacology, University of the Basque Country (UPV/EHU), Leioa, Bizkaia 48940, Spain.
E-mail: javier.meana@ehu.es
Keywords: Munc18-1a; PPI; schizophrenia; SNARE
Citation: Transl Psychiatry (2013) 3, e221; doi:10.1038/tp.2012.149
& 2013 Macmillan Publishers Limited All rights reserved 2158-3188/13
www.nature.com/tp
used for experimental and Other Scientific Purposes
(European Union Directive #86/606/EEC). All animals were
3- to 6-month-old males.
Generation of the transgenic animal. Animals were
created by pronuclear microinjection to C57BL6/CBA
embryos.16 A sequence of 2848 nucleotides from the
GTRAP3-18 promoter was amplified by PCR and cloned
using the KpnI–SalI sites, in the right anterior position of
human Munc18-1a cDNA (NIH_MGC_94), in the pCMV-
Sport6 commercial vector. The construct was digested
and the transgene microinjected in mouse embryo. This
transgene fragment, in addition to the GTRAP3-18 promo-
ter and the cDNA sequence for Munc18-1a (clone
IRAVp968D0260D, www.imagenes-bio.de), contained a
SV40 polyadenylation site for mRNA stabilization. Four
transgenic founders were produced and in three of them
(lines L3, L7 and L8), the transgene was Mendelian fashion
transmitted. Immunoblotting analysis showed that line L8
did not display increased expression of munc18-1a
(Supplementary Figure S1) while line L3 presented impaired
breeding. After initial animal characterization of the three
lines (data not shown), line L7 (termed as Munc18-OE) was
selected for further assays.
Quantitative real-time PCR. QRT–PCR was performed
with a StepOnet thermocycler using a TaqMant assay
(Applied Biosystems, Foster City, CA, USA) specifically
designed for recognizing munc18-1a. Data were analyzed
with the StepOnet Software v2.1 (Applied Biosystems). This
procedure has been described earlier.17
In situ hybridization. Sections (20 mM) were thaw mounted
onto slides and pre-treated using a protocol previously
described.18 An oligonucleotide complementary to mouse
munc18-1a mRNA was labeled with [35S]dATP. After
incubation with the labeled probe, slides were washed, air
dried and exposed to films together with 14C microscales at
 20 oC for 4 weeks. Experiments were quantified using
Scion Image system (Scion Corporation, Frederick, MD,
USA).
Immunoblotting. Immunoblotting procedures were carried
out as described earlier.19 Briefly, electrophoresis was
carried out and membranes were incubated with specific
antibodies (Supplementary Table S1). Later, the membranes
were incubated with the respective secondary antibodies,
visualized on X-ray film by chemiluminescence and quanti-
fied by densitometry.
Immunofluorescence. The brains were fixed by
transcardial perfusion (4% paraformaldehyde) and cryopro-
tected in 30% sucrose. The sections (30mM) were blocked
and incubated at 4 1C with anti-munc18-1a antibody. Sec-
tions were washed and incubated with the secondary
antibody. Fluorescence microscopic analyses were per-
formed with a Nikon microscope (Kanagawa, Japan). Twenty
different fluorescence images were carried out in each
mouse. Gray intensities in arbitrary units were measured in
each image.
Novelty-induced hyperactivity. Mice were placed indivi-
dually in the center of an open field and spontaneous
locomotion was evaluated for 105min with a computerized
video-tracking system (SMART, PanLab, Spain).
DOI-induced head-twitch. Mice were injected with
1mg kg 1 i.p. of DOI (2,5-dimethoxy-4-iodoamphetamine)
and, 5min after injection, recorded for 10min.20 Subsequent
head-twitch response (HTR) was scored.
Elevated plus maze. Mice were individually placed in the
maze and time spent in open-arms and number of entries to
open-arms were evaluated for 5min.21
Social interaction. Pairs of mice from different home-cages
were placed together and the time that mice socially interact
was measured for 5min.21
Novel object recognition test. Animals were given two
sample sessions and one test trial. In sample 1, the animal
was allowed 5min to explore four identical novel objects
(object A) arranged in a triangular shape. In sample 2, the
animal explored four new identical objects (object B)
arranged in a rectangular shape. Finally, the animal was
given a test trial in which two copies of object B were placed
as in sample 2, one copy of object A was placed as it had
been in sample 1, and one copy of object A was newly
located. Exploration was recorded and scored for investiga-
tion time of each object in both sample and test sessions.
Prepulse inhibition of the startle reflex. Mice were placed
in a startle chamber (PanLab, Spain) and then subjected to a
pseudo randomized combination of: (1) 10 pulse-alone trials
consisted of a single white noise burst; (2) 10 prepulse-alone
trials for each prepulse intensity; (3) 10 prepulse–pulse trials
for each prepulse intensity; (4) 10 presentations of no
stimulus trial, in which only the background noise was pre-
sented. Prepulse inhibition (PPI) was calculated as a percen-
tage score: %PPI¼ [100 (startle response to prepulseþ
pulse trial)/(startle response to pulse-alone trial)] 100.
Amphetamine-induced behavioral sensitization. Mice
were injected with amphetamine (5mgkg 1, i.p.) and
spontaneous locomotion was evaluated with a computerized
video-tracking system (SMART, PanLab) for 105min after
injection.
In vivo microdialysis and chromatographic analysis.
Animals were anesthetized and placed in a Kopf stereotaxic
frame. Intracerebral probes (Cuprophan 2mM membrane)
were implanted in the striatum (coordinates AP þ 1.2mM,
L þ 1.5mM, DV  3.2mM) or in the prefrontal cortex
(AP þ 2.0mM, L þ 0.3mM, DV  3.4mM)22 and fixed
to the skull. The next day, mice were connected to a
fraction collection system for freely moving animals.23
Basal values were obtained by no-net-flux method
and response to amphetamine (5mg kg 1 i.p.) was calcu-
lated over basal values. Dopamine (DA) concentrations
were measured by HPLC coupled to an electrochemical
detector.
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Caspase-3. Caspase-3 activity was measured by cleaving
the selective substrate Ac–Asp–Glu–Val–Asp–AFC (Biomol
International, Plymouth Meeting, PA, USA). Brain cortex was
homogenized and centrifuged, and samples were incubated
in a total volume of 100 ml comprised of 80 ml detection buffer.
After incubation, cleavage of the substrate was detected
measuring fluorescence with a Fluoroscan Ascent reader
(Labsystems, Waltham, MA, USA).
Lipid peroxidation. Brain cortex was sonicated and depro-
teinized with 40% trichloroacetic acid and 5M HCl, followed
by the addition of 2% thiobarbituric acid in 0.5 M NaOH.
The reaction mixture was heated at 90 1C for 15min and
centrifuged at 12 000 g for 10min. The pink chromogen
was measured at 532 nM in a Beckman DU-7500 spectro-
photometer (Beckman Coulter, CA, USA).
Volumetric study of gray matter. Animals were anesthe-
tized with sevoflurane (4% for induction and 2% for main-
tenance in 100% O2). Images were acquired with a Bruker 7/
210 USR MRI scanner (Bruker Instruments, Billerica, MA,
USA). A T2-weighted spin echo sequence was acquired with
the following parameters: 256 256 matrix size covering a
field of view of 20mM, repetition time 3100 s, echo time
35ms, 37 slices with slice thickness 0.4mM. Cerebral gray
matter differences between groups were studied applying
VBM (voxel-based morphometry) methodology with SPM5
software package (Statistical Parametric Mapping, Wellcome
Department of Cognitive Neurology, London, UK). Tissue
probabilities maps, created with wild-type (WT) and R6/2
transgenic c57 mice, were provided by the author of the
spmmouse extension.24 VBM statistical analysis consisted of
a Student’s t-test, with the gray matter volume as a covariate,
and FDR (false discovery rate) correction for multiple compari-
sons. Significant results were accepted for Po0.01 (corrected
for FDR) and a minimum cluster size of 200 voxels.
Data analyses and statistics. Data were analyzed with
GraphPad PrismTM 4.0 (GraphPad Software, San Diego, CA,
USA), except for volumetric assay of gray matter. Results are
expressed as mean±s.e.m. values. Data were analyzed by
using unpaired Student’s t-test, one-way or two-way analysis
of variance tests followed by Bonferroni post hoc test
for multiple comparisons. The level of significance was set
to Po0.05. All tests were two tailed.
Results
Selective overexpression of munc18-1a in the brain of
transgenic mice. Munc18-1a expression was driven by the
GTRAP3-18 promoter, which regulates EAAT3, a neuronal
product expressed in glutamatergic and GABAergic
neurons.25,26 Increased expression of munc18-1a was
observed in the brain cortex of the transgenic Munc18-OE
mice by QRT–PCR (Figure 1a). An anatomical distribution of
the mRNA encoding for munc18-1a protein was observed by
in situ hybridization through different structures of the mouse
brain. The specificity of munc18-1a mRNA labeling was
demonstrated by the displacement with unlabeled oligonu-
cleotide (Figure 1bA´´, B´´ and C´´). Thus, strong hybridization
signals were observed in the cerebellum. Intermediate
signals were detected over piriform cortex and, at a lesser
extent, in hippocampus (CA1, CA3 and dentate gyrus) and
some cortical areas such as entorhinal cortex (Figure 1bA´, B´
and C´). Using this technical approach, a significant increase
in the munc18-1a mRNA labeling was observed in cerebel-
lum and piriform and entorhinal cortex of Munc18-OE when
compared with WT control animals (Figure 1c). Munc18-1a
protein immunodensity increased in the brain cortex of
Munc18-OE mice (Figure 1d) while munc18-1b did not
change (Figure 1e). Enhanced munc18-1a protein immuno-
fluorescence (Figure 1f) was found in cortex, hippocampus
and cerebellum of the Munc18-OE mice (Figure 1g).
SNARE complex components. Neurotransmission pro-
cesses are subjected to the control of exocytosis machinery,
in which SNARE complex proteins play the key role.27
Syntaxin-1A, SNAP-25 and synaptobrevin, as well as
synaptotagmin, did not change in the brain cortex of
Munc18-OE mice. Stable heterotrimeric SNARE complexes
in cortex showed no differences between Munc18-OE and
WT controls (Supplementary Figure S2).
Schizophrenia-related phenotype. Munc18-OE and age-
and sex-matched WT controls were subjected to a battery of
tests for investigating schizophrenia-related behaviors.
Munc18-OE mice spent less time exploring the center
(Figure 2a) and more time the periphery (Figure 2b) of the
open-field, consistent with an anxiety-like phenotype. In the
novelty-induced hyperactivity test, the Munc18-OE mice
exhibited increased locomotor activity during the first
5min, which is described as a schizophrenic-like beha-
vior15,28 (Figure 2c). No differences were found in the
holeboard test for exploratory behavior (Supplementary
Figure S3a) or in the rotarod test for motor coordination
(Supplementary Figure S3b). In the elevated plus-maze test,
Munc18-OE mice spent less time in the open-arms
(Figure 2d) while decreased the number of entries to the
open-arms (Figure 2e). These results reveal a high grade of
aversion to unprotected spaces displayed by the Munc18-OE
mice, which could mimic some of the negative symptoms of
schizophrenia.
Deficits in social functioning represent a core negative
symptom in schizophrenia and provide a quantifiable ‘nega-
tive symptom-like’ behavior in animal models.14,15,29 Munc18-
OE mice showed a decrease in social interaction (Figure 2f).
There were no changes in immobility time in the forced swim
test in Munc18-OE mice (Supplementary Figure S3c),
suggesting the absence of depressive-like symptoms.
Serotonin 5HT2A hallucinogenic drugs induce a quantifiable
HTR in rodents that is not induced by non-hallucinogenic
5HT2A agonists. There are data supporting the HTR as a valid
behavioral proxy of positive symptoms of psychosis in mice.30
Munc18-OE mice exhibited an increased HTR to administra-
tion of the hallucinogen 5HT2A agonist drug DOI (Figure 2g)
when compared with WT controls.
Memory deficits in Munc18-OE mice were investigated by
testing the animals on an episodic memory task for objects
(‘what’), their locations (‘where’) and the order in which they
were experienced (‘when’) (Figure 2h). Munc18-OE mice
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exhibited significant lower score in the memory for ‘what’.
Moreover, a significant decrease in score for ‘where’ memory
was also found in Munc18-OE mice as well as in ‘when’
memory. These data suggest alterations in recognition
memory processes, which have been described to be
disrupted in schizophrenia.31 No differences were found in
the Morris water-maze test (Supplementary Figure S3d),
indicating that spatial memory is not affected in these
transgenic animals.
Since PPI deficits have been reported in schizophrenia
patients,32 Munc18-OE and WT mice were subjected to the
PPI test in order to evaluate sensorimotor gating processes.
Figure 1 Characterization of Munc18-OE transgenic mice. (a) Quantitative real-time PCR study showed significant increased mRNA levels of munc18-1a in the brain
cortex of Munc18-OE mice (unpaired t-test *Po0.05 versus wild-type (WT) controls). (b) Representative autoradiograms showing the distribution of munc18-1a mRNA in
coronal sections of WT controls (A, B, C) and transgenic Munc18 mice (A´, B´, C´). The specificity labeling was demonstrated by the displacement with unlabeled oligonucleotide
(A´´, B´´, C´´). Note the increase of mRNA signal in cerebellum and piriform cortex. Pir, piriform cortex; CA1, CA1 field of hippocampus; CA3, CA3 field of hippocampus; DG,
dentate gyrus; CB Cx, Cerebellum cortex. Bar: 2 mm. (c) Expression of mRNA encoding for munc18-1a in Munc18-OE and WT control mice evaluated by in situ hybridization.
Significant increases of munc18-1a mRNA levels were obtained in different brain regions of Munc18-OE (unpaired t-test *Po0.05, **Po0.01 and ***Po0.005 versus WT
control group). (d) Increased immunodensity of munc18-1a protein in the brain cortex of Munc18-OE mice (unpaired t-test **Po0.005 versus WT controls). Representative
immunoblots of munc18-1a and b-actin in WT controls and Munc18-OE mice. (e) As a negative control, no differences were found in munc18-1b protein expression between
Munc18-OE and WT controls. (f) Representative images of munc18-1a distribution in WT (left panels) and Munc18-OE (right panels) at 10 , green (munc18-1a) and blue
(nuclei) in cortex (cx), hippocampus (hp) and cerebellum (cb). (g) Increased immunofluorescence in different brain areas of Munc18-OE mice (unpaired t-test **Po0.005 and
***Po0.0001 versus WT controls); cx, cortex; hp, hippocampus; cb, cerebellum; str, striatum. Data are mean±s.e.m.; the number of animals is indicated in parentheses or
inside plot bars.
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Munc18-OE mice exhibited a significant decrease in the PPI
of the acoustic startle reflex at different intensities (Figure 2i),
while no differences were found in the startle amplitude
between transgenic Munc18-OE and WT controls. Acute
clozapine (1.5mg kg 1 i.p.) reversed the PPI deficits in
Munc18-OE mice while exerted no changes in WT controls
(Figure 2i).
Dopaminergic system alterations. DA signaling dysregu-
lation has been proposed as a crucial component of the
pathophysiology of schizophrenia.2 D1 receptor density
decreased in both cortex and striatum of Munc18-OE mice
(Figure 3a) while D2 receptor density did not change
(Figure 3b). Similar alterations of D1 and integral components
of its signal transduction pathways have been found in
patients with schizophrenia.33,34 The DA membrane
transporter (DAT) is a critical regulator of DA neurotransmis-
sion in the brain. Due to the difficulty of DAT immunodetec-
tion in cortical regions, striatal DAT was evaluated and a
strong decrease was found in Munc18-OE mice (Figure 3c).
These data are in accordance with those studies reporting an
in vivo decrease of DAT in patients with schizophrenia.35
This decrease of DAT suggests that intracellular pools
of DA would probably be altered. Therefore, TH (tyrosine
hydroxylase) was evaluated and results showed increased
density in both cortex and striatum of Munc18-OE mice
(Figure 3d). Basal extracellular concentrations of DA in both
regions were no different between Munc18-OE mice and
their controls. However, administration of a single dose of
amphetamine (5mgkg 1 i.p.) induced an enhanced loco-
motor hyperactivity (Figure 3e) and higher increase of
extracellular DA in both prefrontal cortex (Figure 3f) and
striatum (Figure 3g) of Munc18-OE when compared with WT
controls. Similar supersensitivity to amphetamine-induced
increase of DA release has been described in schizophrenic
patients when evaluated by in vivo neuroimaging.36
Glutamate receptors. Abnormalities in glutamate neuro-
transmission have been implicated in major psychiatric
disorders such as schizophrenia.37 No changes of mGluR2
and mGluR3 receptors (Supplementary Figure S4a),
AMPAR1, AMPAR2/3/4 (Supplementary Figure S4b), NR1
and NR2A (Supplementary Figure S4c) protein subunits
were found in the brain cortex of Munc18-OE mice. No
changes of the glutamate signaling activation protein PSD95
were observed (Supplementary Figure S4d). Src, a kinase
Figure 2 Overexpression of munc18-1a leads to schizophrenia-related behaviors. (a, b) Decreased central locomotion following exposure to a novel environment and
increased exploration of the peripheral area in Munc18-OE transgenic mice (repeated-measures analysis of variance (ANOVA) followed by Bonferroni post hoc test,
**Po0.01 and ***Po0.001 versus wild-type (WT) controls). (c) Increased locomotor activity of the transgenic mice during the first 5 min in novelty-induced hyperactivity test
(unpaired t-test *Po0.05 versus WT controls). No differences between Munc18-OE and WT controls were found in total distance traveled in open field. (d) Munc18-OE mice
displayed anxiety-like behavior in the elevated plus maze, as shown by the decreased time in open-arms (unpaired t-test *Po0.05 versus WT controls) and the decreased
number of entries into open-arms (e) (unpaired t-test **Po0.01 versus WT) (f) The social interaction test revealed decreased time of interaction elicited by transgenic Munc18-
OE mice (unpaired t-test **Po0.01 versus WT controls). (g) Increased sensitivity to hallucinogenic-like action in Munc18-OE mice as shown by the increased number of head-
twitch responses to DOI (1 mg kg 1, i.p.) administration (unpaired t-test *Po0.05 versus WT controls). (h) Transgenic Munc18-OE mice exhibited altered episodic memory as
shown in the novel-object recognition test. Decreased score in memory for objects (what), their locations (where), and the order in which they were experienced (when)
(unpaired t-test *Po0.05 and **Po0.005 versus WT controls). (i) Munc18-OE mice showed impaired prepulse inhibition (PPI) of the acoustic startle reflex across prepulse
intensities (two-way analysis of variance (ANOVA) ***Po0.001 for genotype factor; unpaired t-test *Po0.05 and **Po0.005 versus WT controls). Impairment of the PPI was
completely reversed in the transgenic mice after clozapine (1.5 mg kg 1 i.p.) administration (unpaired t-test #Po0.05 versus transgenic animals with saline). No differences
were found in the startle amplitude between Munc18-OE and WT controls. Data are mean±s.e.m.; the number of animals is indicated in parentheses or inside the plot bars.
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that phosphorylates and subsequently activates NR2A
subunits, was also evaluated and no differences were found
(Supplementary Figure S4e).
In vivo volumetric study of gray matter loss. Numerous
findings from imaging studies strongly support that decre-
ments of gray matter volume are involved in schizophre-
nia.3,4 The magnetic resonance imaging (MRI) volumetric
study revealed a significant reduction of gray matter volume
in Munc18-OE mice (Supplementary Table S2) in right and
left temporal cortex (Figure 4a), prefrontal–olfactory cortex
(Figure 4b) and cerebellar lobe (Figure 4c).
Changes in apoptotic and inflammatory markers.
Several studies have suggested a role of apoptotic pathways
in the cortical brain volume deficits in schizophrenia.38 Fas
receptor showed no changes in Munc18-OE mice
(Figure 5a), FADD protein increased and no changes were
observed in p-Ser191-FADD (Figure 5b). Caspase-3 activity
(Figure 5c) and PARP-1 density did not change in Munc18-
OE (Figure 5d). Oxidative insults are well-established
triggers of apoptosis and oxidative stress has been impli-
cated in the pathophysiology of schizophrenia.39 Munc18-OE
exhibited an increase of inducible nitric oxide synthase
(NOS2) density in the brain cortex whereas no changes were
observed in cyclooxygenase 2 (COX2) or in neuronal nitric
oxide synthase (NOS1) (Figure 5e). Malondialdehyde (MDA)
cortical levels were quantified to test whether lipid peroxida-
tion could be altered in Munc18-OE animals although
no changes were found (Figure 5f).
Discussion
This study demonstrates that munc18-1 is involved in the
development of behavioral, neurochemical andmorphological
changes that resemble those observed in schizophrenia.
Munc18-OE mice seem to fulfill the validity requirements for
an animal model of schizophrenia.14,15,28 Thus, the transgenic
Munc18-OE animal: (a) was developed on the basis of
precvious findings in human brain of subjects with
Figure 3 Alterations of dopaminergic system components. (a) Munc18-OE mice displayed decreased dopamine D1 receptor density versus wild-type (WT) controls in both
cortical and striatal brain regions (unpaired t-test *Po0.05 and **Po0.0001 versus WT controls). Representative immunoblots of dopamine D1 receptor and b-actin in WT
controls and Munc18-OE mice. (b) No differences were observed in dopamine D2 receptor immunodensity between transgenic Munc18-OE and WT control mice. (c) Striatal
dopamine transporter (DAT) was strongly decreased in Munc18-OE mice (unpaired t-test *Po0.001 versus WT controls). Representative immunoblots of DAT and b-actin in
WT controls and Munc18-OE mice. (d) Munc18-OE mice exhibited an increase of the dopamine synthesizing enzyme tyrosine hydroxylase (TH) in both cortex and striatum
(unpaired t-test *Po0.05 and ***Po0.0001 versus WT controls). Data bars of immunoblots are mean (percentage over controls)±s.e.m.; the number of animals is indicated
in parentheses. (e) Increased motor activity in Munc18-OE mice (m) versus WT controls (J) following a single injection of 5 mg kg 1 i.p. of amphetamine (Amph) (repeated-
measures two-way analysis of variance (ANOVA) followed by Bonferroni post hoc test, *Po0.05 and **Po0.01 versus WT). (f, g) Effect of Amph (5 mg kg 1 i.p.) on
extracellular DA concentrations in the prefrontal cortex (f) or striatum (g) of Munc18-OE mice (K) and their WT controls (J) expressed as percentage of DA basal
concentration values (two-way ANOVA followed by Bonferroni post hoc test, *Po0.05 and ***Po0.001 versus WT controls). The mean of the six first samples were
considered basal values and assumed as the 100% value. Values were expressed as percentage of the basal values. Points are mean±s.e.m.; the number of animals is
indicated in parentheses.
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schizophrenia10,11 (construct validity); (b) exhibits schizo-
phrenia-related phenotypes (face validity); and (c) normalizes
PPI deficits following antipsychotic drug treatment (predictive
validity). Furthermore, the present study strongly supports the
hypothesis that abnormalities in exocytosis play a key role in
the pathophysiology of schizophrenia.
Dysregulation of munc18-1 in postmortem brain of schizo-
phrenic subjects is still controversial. Thus, increased
expression in membrane microdomains,10 unaltered expres-
sion in total protein11 and decreased coimmunoprecipitation
with syntaxin-1 of munc18-19 have been described in the brain
of schizophrenic subjects. The Munc18-OE mouse design
was based on the overexpression of the munc18-1 protein10
and the downregulation exerted by antipsychotics11 in human
brain.
Overexpression of munc18-1 induces a spectrum of
behaviors that correlates with symptoms observed in schizo-
phrenia.28 This model displayed anxiety-like behaviors and
aversion to unprotected new situations as observed in
novelty-induced hyperlocomotion or elevated plus-maze
tests. It has been described that patients with schizophrenia
often develop additional comorbid conditions, including
anxiety disorders.40 On the other hand, animals overexpres-
sing munc18-1 did not present a depressive-like behavior, at
least in the test used in this study for evaluation of depressive
behaviors. Deficits in social functioning, which represent a
core negative symptom in schizophrenia,29 were also present
in these transgenic mice as revealed the decreased social
interaction. Moreover, these mice displayed cognitive altera-
tions that resemble cognitive deficits observed in
schizophrenia.40
The PPI deficits observed in Munc18-OE mice evidenced
the existence of profound alterations in sensorimotor gating
processes. PPI test has been considered as an excellent tool
for studying the neural basis of schizophrenia due to the
relevance of deficits in filtering sensorial and cognitive
information in the pathophysiology of this disorder.32 The fact
that the atypical antipsychotic clozapine completely reversed
the gating deficit strongly supports the Munc18-OE as an
animal model that mimics schizophrenia. In addition, the
increase in hallucinogenic-like response susceptibility, as
demonstrated the effects of DOI administration, might indicate
that Munc18-OE is a good model for this positive core
symptom of psychosis and schizophrenia.
DA signaling dysregulation has been proposed as a crucial
component of the pathogenesis of schizophrenia2 and it has
been suggested that abnormal cognitive functioning in schizo-
phrenia is related to alteredDA function in the prefrontal cortex.33
The Munc18-OE mice showed a decrease of D1 without
changes of D2 receptor protein in both brain cortex and
striatum. Studies in humans have shown controversy
about D1 receptor in schizophrenia. Some binding
studies have reported decreased prefrontal D1 receptors in
Figure 4 Volumetric reduction in gray matter of Munc18-OE transgenic mice.
(a) A reduction in volume in temporal cortex was observed, Po0.01, K¼ 200
voxels, T¼ 5.66 (left side) and 6.02 (right side). (b) A reduction in volume in
prefrontal–olfatory–cingulate cortex was shown, Po0.01, K¼ 200 voxels,
T¼ 8.11, as well as in (c) cerebellar lobe Po0.01, K¼ 200 voxels, T¼ 5.25.
Images were analyzed according to voxel-based morphometry (VBM) methodology
(see Materials and methods for details). Color bar indicates potency of significance
level, from 0 (less potency) to 8 (more potency).
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schizophrenia,34,41 while others have found no changes42 or
even an increase in D1 binding potential.
43 Increased binding
of D1 does not necessary represent an overexpression of the
receptor, since it might be due to an increase in receptor
affinity.44 Despite these confusing data, it has been postulated
that both upregulation and downregulation of D1 receptors
in the prefrontal cortex are closely related to cognitive
symptoms.33,43 D2 receptors are widely expressed in striatal
areas and their regulation in schizophrenia is also a focus of
discussion. Imaging studies have found no changes of D2
receptors in treatment-naive patients with schizophrenia,45
while in post-mortem human tissue it has been reported an
increase of D2 receptor in striatal areas
44 or even no changes
in prefrontal cortex.19 Moreover, the relationship between
increases of D2 receptors and exposure to antipsychotics is
not still well established and D2 upregulation in schizophrenia
might be induced by neuroleptic long-term treatment.44,46
The DA membrane transporter (DAT) is a critical regulator
of dopaminergic neurotransmission in the brain. In this animal
model, overexpression of munc18-1a led to a strong down-
regulation of DAT in striatum. As occurs with DA receptors,
also the status of DAT in the brain of subjects with
schizophrenia remains unclear. However, DAT knockout mice
have provided an opportunity to model in vivo conditions of
extreme dopaminergic dysfunction.47 DAT knockout mice
exhibit impairment in social interaction48 and deficits in PPI
that are attenuated after antipsychotic administration.49 It has
been postulated that in the absence of DAT, extracellular DA
clearance from synaptic cleft slows down, which leads to the
downregulation of DA receptors.47 The observed strong
decrease of DAT in Munc18-OE might contribute to gating
deficits and social dysfunction. TH was strongly overex-
pressed in cortex and striatum of Munc18-OE. Equivalent TH
overexpression has been demonstrated under conditions of
chronic blockade of DAT by cocaine administration.50
Because of the D1 receptor abnormalities, the reduction of
presynaptic DAT and the overexpression of TH, it is tempting
to speculate the presence of hyperdopaminergia in the brain
of Munc18-OE mice. Hyperactivity of presynaptic DA term-
inals has been proposed to be a key component of
schizophrenia2,51 and should be reflected in alteration of
extracellular DA concentrations under in vivo conditions.
Although basal DA concentrations in the brain cortex and
striatum of Munc18-OE were not modified, amphetamine
challenge promoted an enhanced release of DA when
compared with controls. Similar findings have been reported
by in vivo neuroimaging in patients with schizophrenia.36
Moreover, the enhanced sensitivity of extracellular DA to
amphetamine administration in Munc18-OE is concordant
with the hyperlocomotion observed in these animals in
response to amphetamine. In fact, this hyperactivity has been
proposed as a valuable model for psychosis and positive
symptoms of schizophrenia. All these data reveal that the
dopaminergic dysfunction in Munc18-OE animals might be
Figure 5 Apoptotic pathways and inflammatory markers. (a) No changes in Fas receptor density (glycosylated form), evaluated by western blot, were found in cortex of
Munc18-OE mice. Representative immunoblots of Fas receptor and b-actin in WT controls and Munc18-OE mice (b) FADD (dimeric form) significantly increased in Munc18-
OE mice (unpaired t-test *Po0.05 versus WT controls) while phosphorylated p-191 FADD (oligomeric form) remained unchanged. Representative immunoblots of FADD,
p-191 FADD and b-actin in WT controls and Munc18-OE mice. (c) No changes were found in caspase-3 activity. (d) No aberrant changes were observed in the proteolytic
cleavage of nuclear PARP-1. Representative immunoblots of PARP-1, 85 fragment and b-actin in WT and Munc18-OE mice. (e) An increase of inducible nitric oxide synthase
(NOS2) was detected in the brain cortex of Munc18-OE (unpaired t-test *Po0.05 versus WT controls). The Munc18-OE mice did not present changes in the pro-inflammatory
enzyme ciclooxygenase 2 (COX2) and in neuronal nitric oxide synthase (NOS1). Representative immunoblots of NOS2/COX2/NOS1 and b-actin in WT controls and Munc18-
OE mice. (f) Lipid peroxidation was studied by measuring the levels of malondialdehyde (MDA) in the brain cortex of Munc19-OE and WT controls. No changes were found in
cortical MDA of Munc18-OE mice when compared with their WT controls. Data bars are mean (percentage over controls)±s.e.m.; the number of animals is indicated in
parentheses or inside the plot bars.
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representative of the spectrum of symptoms observed in
humans with schizophrenia.
Imaging studies suggest that schizophrenia is a brain
disease involving decrements of gray matter volume.3,4 The
significant decrease of graymatter in temporal and prefrontal–
olfactory cortex as well as in cerebellar lobe of Munc18-OE
when evaluated by MRI revealed the importance of this model
for the study of the schizophrenia pathogenesis. Although
mechanisms underlying the decrease of cortical brain volume
in schizophrenia are unknown, it could suggest a role of
apoptotic pathways in these deficits.38 Changes of apoptotic
pathways in cortex of Munc18-OEmice were scarce but a pro-
apoptotic trend in apoptosis pathways and susceptibility to
neural damage induced by elevated NOS2 might be con-
tributing to the reported decreases of gray matter. Further
studies beyond this exploratory analysis of the Munc18-OE
phenotype are necessary to establish the mechanisms
leading from munc18-1a overexpression to regional brain
loss of gray matter.
Since schizophrenia is a disorder with non-well understood
origin, pathogenesis, and pathophysiology, animal models
could contribute to decipher the key components of the
disease and its response to treatment. In this context, the
present study demonstrates that dysfunctions of munc18-1
are relevant for the development of a wide spectrum of
behavioral, neurochemical and anatomical alterations that
may resemble schizophrenic symptoms and/or neurobiologi-
cal findings observed in subjects with schizophrenia.
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